# A Study of WX390 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06117540/  
OnCo record `nct06117540` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of WX390 in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.

## Summary

A Study of WX390 in Patients With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06117540 by Shanghai Jiatan Pharmatech Co., Ltd, with 70 participants planned, started 2021-05-11 and due to reach its primary completion in 2025-06-12. Interventions recorded: WX390.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06117540
- Phase: 2
- Setting: An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors
- Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT06117540: https://clinicaltrials.gov/study/NCT06117540

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06117540.json